ArticleChemistry & biology2011
BCR-ABL1 kinase: hunting an elusive target with new weapons.
Article in Chemistry & biology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Long-Term Safety and Clinical Effects of Nilotinib in Parkinson's Disease.Movement disorders : official journal of the Movement Disorder Society · 2021Trial
- Nilotinib Effects on Safety, Tolerability, and Potential Biomarkers in Parkinson Disease: A Phase 2 Randomized Clinical Trial.JAMA neurology · 2020Trial
- Pharmacokinetics and pharmacodynamics of a single dose Nilotinib in individuals with Parkinson's disease.Pharmacology research & perspectives · 2019Trial
- Nilotinib Effects in Parkinson's disease and Dementia with Lewy bodies.Journal of Parkinson's disease · 2016Trial
- Therapeutic strategies for tauopathies and drug repurposing as a potential approach.Biochemical pharmacology · 2022Review
- Nilotinib Effects on Safety, Tolerability, and Biomarkers in Alzheimer's Disease.Annals of neurology · 2020Article
- Article
- BMS-708163 and Nilotinib restore synaptic dysfunction in human embryonic stem cell-derived Alzheimer's disease models.Scientific reports · 2016Article
- Nilotinib-induced autophagic changes increase endogenous parkin level and ubiquitination, leading to amyloid clearance.Journal of molecular medicine (Berlin, Germany) · 2014Article
- Is human immunodeficiency virus-mediated dementia an autophagic defect that leads to neurodegeneration?CNS & neurological disorders drug targets · 2014Review
- Anti-oxidant vitamin E prevents accumulation of imatinib-resistant BCR-ABL1 kinase mutations in CML-CP xenografts in NSG mice.Leukemia · 2013Article
- Nilotinib reverses loss of dopamine neurons and improves motor behavior via autophagic degradation of α-synuclein in Parkinson's disease models.Human molecular genetics · 2013Article
- Tyrosine kinase inhibition increases functional parkin-Beclin-1 interaction and enhances amyloid clearance and cognitive performance.EMBO molecular medicine · 2013Article
- BCR-ABL1 kinase inhibits uracil DNA glycosylase UNG2 to enhance oxidative DNA damage and stimulate genomic instability.Leukemia · 2013Article
- Genetic mechanisms of chronic myeloid leukemia blastic transformation.Current hematologic malignancy reports · 2012Review
Corrections and comments
- Comment on
Authors and funding
1 author.
Funding
Abstract
Tyrosine kinase inhibitors such as imatinib, dasatinib, and nilotinib interfere with ATP-binding pocket to inhibit BCR-ABL1 kinase. A recent report in Cell by Grebien et al. paves the way for a new approach to target BCR-ABL1 kinase by interfering with its SH2-kinase domain interface.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.